Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMOF95
|
|||
| Drug Name |
Tezepelumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Severe asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Approved | [1] | |
| Company |
Amgen; AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thymic stromal lymphopoietin (TSLP) | Target Info | Blocker | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| WikiPathways | TSLP Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761224. | |||
| REF 2 | Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.